New drug constellations for glaucoma

Francisco Yunier Fumero González; Daylin Cárdenas Chacón; Ibraín Piloto Díaz; Marerneda Domínguez Randulfe; Yuderkys Díaz Águila; Lizet Sánchez Acosta; Dayamis Núñez Fuentes

2017, Number 4

<< Back Next >>

Rev Cub Oftal 2017; 30 (4)

New drug constellations for glaucoma

Fumero GFY, Cárdenas CD, Piloto DI, Domínguez RM, Díaz ÁY, Sánchez AL, Núñez FD

Full text

How to cite this article

Language: Spanish
References: 0
Page: 1-6
PDF size: 57.36 Kb.

ABSTRACT

The present review is aimed at presenting the new therapeutic options to treat glaucoma. Medical treatment of glaucoma has undergone surprising progress as of the emergence of new hypotensive collyriums. Various firms are currently conducting research into the simplest, most effective and best tolerated therapeutic alternatives. Prostaglandin analogues are considered to be the first line therapy, but new, promising drugs are also being developed, such as latanoprostene bunod (Vesneo), netarsudil 0.02 % (Rhopressa), trabodenoson (Inotek Pharmaceuticals) and other sustained release compounds. A large number of clinical assays have been implemented and many publications have been made in the United States, the European Union and Japan which, curiously enough, have been given names of planets or constellations.